To include your compound in the COVID-19 Resource Center, submit it here.

Uncertainty weighs

Regulatory doubts overhang positive teratogenicity data for Vivus obesity drug

Uncertainty weighs

Good teratogenicity data didn't help Vivus Inc. (NASDAQ:VVUS) last week, as the general regulatory uncertainty around obesity drugs likely weighed on investors. The stock was off $0.11 on the week to $8.23.

The biotech announced results

Read the full 362 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE